Hormone Replacement Therapy and Haemostatic Function

• References

• 1 Falkebom M, Persson I, Adami HO. et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet & Gynaecol 1992; 99: 821-828
• 2 Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 453-461
• 3 Falkeborn M, Persson I, Terent A. et al. Hormone replacement therapy and the risk of stroke. Arch Intern Med 1993; 153: 1201-1209
• 4 Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-980
• 5 Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981-983
• 6 Daly E, Vessey MP, Painter R, Hawkins MM. Case-control study of venous thromboembolism risk in users of hormone replacement therapy. Lancet 1996; 348: 1027
• 7 Pérez Gutthann S, Garcia Rodriguez LA, Castellsague J, Oliart AD. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. Br Med J 1997; 314: 796-800
• 8 Grodstein F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Speizer FE, Willett WC, Hennekens CH. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983-987
• 9 Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Br Med J 1996; 312: 83-88
• 10 Lewis MA, Spitzer WO, Heinemann LAJ, MacRae KD, Bruppacher R, Thorogood M. Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. Br MedJ 1996; 312: 88-90
• 11 Medical Research Vouncil’s General Practice Research Framework. Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in hysterectomised women. Report from MRC’s General Practice Research Framework. Br Med J 1996; 312: 473-478
• 12 The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995; 273: 199-208
• 13 Munk-Jensen N, Ulrich LG, Obel EB, Neilsen SP, Edwards D, Meinertz H. Continuous combined and sequential estradiol and norethindrone acetate treatment of postmenopausal women: effect on plasma lipoprotein in a two-year placebo-controlled trial. Am J Obstet Gynecol 1994; 171: 132-138
• 14 Caine YG, Bauer KA, Barzegar S. et al. Coagulation activation following estrogen administration of postmenopausal women. Thromb & Haemostas 1992; 68: 392-395
• 15 Kroon U-B, Silfverstolpe G, Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thromb & Haemostas 1994; 71: 420-423
• 16 The Writing Group for the Estradiol Clotting Factors Study. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a 1-year, double-blind, placebo-controlled study. Thromb Haemostas 1996; 75: 476-480
• 17 Scarabin PY, Alhenc-Gelas M, Plu-Burean G, Taisne P, Agher R, Aiach M. Activation of blood coagulation and increased fibrinolytic potential induced by oral but not percutaneous estrogen/progesterone replacement therapy in postmenopausal women: a randomised controled trial. Haemostasis 1996; 26: 466
• 18 Koh KK, Mincemoyer R, Bull MN, Csako G, Pucino F, Guetta V, Waclawiw M, Cannon RO. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997; 336: 683-690
• 19 Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, Szklo M. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993; 328: 1069-1075